The CEO of Mylan (MYL) is headed to Capitol Hill on Wednesday to answer for the skyrocketing cost of the company's EpiPen allergy treatment.
Heather Bresch will defend her company before the House Oversight Committee by saying the company isn't pocketing massive profits by jacking up the cost of the EpiPen, according to her prepared testimony.
Mylan CEO to answer for EpiPen price hikes
Mylan CEO to answer for EpiPen price hikes
http://rss.cnn.com/rss/money_news_international.rss
Nessun commento:
Posta un commento